Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Noninvasive Cancer Diagnostics Market: By Product By Application, By Technique, By Distribution Channel and By Geography
Noninvasive Cancer Diagnostics Market size was valued at US$ 193.2 billion in 2022, growing at a CAGR of 7.4% from 2023 to 2029. The noninvasive technique is a procedure that does not require insertion of an instrument through the skin. With the advancements in the technology, there are various treatment procedures that are being used. The advent of the modern diagnostic techniques helps in the detection of cancer. The noninvasive techniques play a vital role in the diagnosis of cancer replacing the invasive tests. Noninvasive Cancer Diagnostics Market is a method of diagnosing a condition that does not require or requires only minor body incisions. These techniques include determining genetic structure, biomarkers, alterations in molecular biology, and imaging technologies, among others. Cancer is a disease caused by a genetic change in the cells, resulting in uncontrolled development and the formation of a tumor-like structure. Imaging is the primary method of cancer detection, but it does not allow for genetic access; on the other hand, biopsies that allow for genetic access are complicated and difficult to do repeatedly during cancer diagnosis and treatment. As a result, innovative approaches such as molecular diagnostics, serum-based immunoassays, and chemical tests have been developed to identify chemical components in the body, particularly from blood and urine.
Study Period
2024-2030Base Year
2023CAGR
7.4%Largest Market
North AmericaFastest Growing Market
North America
Increase in the prevalence of chronic diseases such as cancer is the key factor attributed for the growth of the noninvasive cancer diagnostics market. The technological advancements play a vital role in the development of the noninvasive techniques. Rising demand for the noninvasive and minimally invasive diagnosis is adding fuel for the growth of the market. The growing geriatric population along with growing health issues and rising awareness among the patient population regarding various treatment options is boosting the growth of the noninvasive cancer diagnostics market. The initiation taken by the government and non-profitable organizations to create awareness regarding the early diagnosis of the disease is anticipated to drive the growth of the noninvasive cancer diagnostics market.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2022 |
US$ 193.2 billion |
Market CAGR |
7.4% |
By Product |
|
By Application |
|
By Technique |
|
By Distribution Channel |
|
Download Free Sample Report
The major factors driving the market growth are the increasing prevalence of various types of cancer, such as lung cancer, breast cancer, and more. Also, the increasing geriatric population and increasing awareness about the diagnosis procedures will be anticipated to expand the market of noninvasive cancer diagnostics.
The high cost of treatment and stringent regulatory policies are some restraining factors that obstruct the market’s growth.
The global noninvasive cancer diagnostics market size is expected to be valued at US$ 193.2 billion in 2021.
Investment and acquisition are the two key strategies opted for prominent companies in the market.
1.Executive Summary |
2.Global Noninvasive Cancer Diagnostics Market Introduction |
2.1.Global Noninvasive Cancer Diagnostics Market - Taxonomy |
2.2.Global Noninvasive Cancer Diagnostics Market - Definitions |
2.2.1.Product |
2.2.2.Application |
2.2.3.Technique |
2.2.4.Distribution Channel |
2.2.5.Region |
3.Global Noninvasive Cancer Diagnostics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Noninvasive Cancer Diagnostics Market Analysis, 2018-2022 and Forecast 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Noninvasive Cancer Diagnostics Market By Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. Test Kits & Reagents |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Consumables |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Noninvasive Cancer Diagnostics Market By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. Lung Cancer |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Breast Cancer |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Solid tumors |
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Blood cancer |
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Noninvasive Cancer Diagnostics Market By Technique, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. Immunochemistry/Immunoassay |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Molecular Diagnostics |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Clinical Chemistry |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Noninvasive Cancer Diagnostics Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. Hospitals |
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Diagnostic Centers |
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Oncology Centers |
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Others |
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9.Global Noninvasive Cancer Diagnostics Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Test Kits & Reagents |
10.1.2.Consumables |
10.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Lung Cancer |
10.2.2.Breast Cancer |
10.2.3.Solid tumors |
10.2.4.Blood cancer |
10.2.5.Others |
10.3. Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Immunochemistry/Immunoassay |
10.3.2.Molecular Diagnostics |
10.3.3.Clinical Chemistry |
10.3.4.Others |
10.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospitals |
10.4.2.Diagnostic Centers |
10.4.3.Oncology Centers |
10.4.4.Others |
10.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Test Kits & Reagents |
11.1.2.Consumables |
11.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Lung Cancer |
11.2.2.Breast Cancer |
11.2.3.Solid tumors |
11.2.4.Blood cancer |
11.2.5.Others |
11.3. Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Immunochemistry/Immunoassay |
11.3.2.Molecular Diagnostics |
11.3.3.Clinical Chemistry |
11.3.4.Others |
11.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospitals |
11.4.2.Diagnostic Centers |
11.4.3.Oncology Centers |
11.4.4.Others |
11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
11.5.6.Rest of EU |
12.Asia Pacific (APAC) Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Test Kits & Reagents |
12.1.2.Consumables |
12.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Lung Cancer |
12.2.2.Breast Cancer |
12.2.3.Solid tumors |
12.2.4.Blood cancer |
12.2.5.Others |
12.3. Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Immunochemistry/Immunoassay |
12.3.2.Molecular Diagnostics |
12.3.3.Clinical Chemistry |
12.3.4.Others |
12.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospitals |
12.4.2.Diagnostic Centers |
12.4.3.Oncology Centers |
12.4.4.Others |
12.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
13.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Test Kits & Reagents |
13.1.2.Consumables |
13.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Lung Cancer |
13.2.2.Breast Cancer |
13.2.3.Solid tumors |
13.2.4.Blood cancer |
13.2.5.Others |
13.3. Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Immunochemistry/Immunoassay |
13.3.2.Molecular Diagnostics |
13.3.3.Clinical Chemistry |
13.3.4.Others |
13.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospitals |
13.4.2.Diagnostic Centers |
13.4.3.Oncology Centers |
13.4.4.Others |
13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
14.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Test Kits & Reagents |
14.1.2.Consumables |
14.2. Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Lung Cancer |
14.2.2.Breast Cancer |
14.2.3.Solid tumors |
14.2.4.Blood cancer |
14.2.5.Others |
14.3. Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Immunochemistry/Immunoassay |
14.3.2.Molecular Diagnostics |
14.3.3.Clinical Chemistry |
14.3.4.Others |
14.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospitals |
14.4.2.Diagnostic Centers |
14.4.3.Oncology Centers |
14.4.4.Others |
14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Digene Corporation (U.S.) |
15.2.2.Gen-Probe Incorporated (U.S.) |
15.2.3.IVDiagnostics, Inc. (U.S.) |
15.2.4.A&G Pharmaceutical, Inc. (U.S.) |
15.2.5.Affymetrix Inc. (U.S.) |
15.2.6.AVIVA Biosciences Corporation (U.S.) |
15.2.7.BIOVIEW Inc. (U.S.) |
15.2.8.Laboratory Corporation of America Holdings (LabCorp) (U.S.) |
15.2.9.Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players